These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24994631)

  • 21. Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics.
    Nogrady B
    BMJ; 2023 Jul; 382():1599. PubMed ID: 37433614
    [No Abstract]   [Full Text] [Related]  

  • 22. "Psychedelic Assisted Therapy" Must Not Be Retired.
    Deckel GM; Lepow LA; Guss J
    Am J Psychiatry; 2024 Jan; 181(1):77-78. PubMed ID: 38161309
    [No Abstract]   [Full Text] [Related]  

  • 23. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
    Haridy R
    Nature; 2023 Jul; 619(7969):227-228. PubMed ID: 37386185
    [No Abstract]   [Full Text] [Related]  

  • 24. A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA.
    Doblin R
    J Psychoactive Drugs; 2002; 34(2):185-94. PubMed ID: 12691208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Turn on and tune in to evidence-based psychedelic research.
    Sessa B
    Lancet Psychiatry; 2015 Jan; 2(1):10-2. PubMed ID: 26359597
    [No Abstract]   [Full Text] [Related]  

  • 26. Neuroscience. Drug find could give ravers the jitters.
    Holden C
    Science; 2002 Sep; 297(5590):2185-7. PubMed ID: 12351758
    [No Abstract]   [Full Text] [Related]  

  • 27. The lure of ecstasy.
    Cloud J
    Time; 2000 Jun; 155(23):62-8. PubMed ID: 10947376
    [No Abstract]   [Full Text] [Related]  

  • 28. Research on psychedelics moves into the mainstream.
    Morris K
    Lancet; 2008 May; 371(9623):1491-2. PubMed ID: 18459186
    [No Abstract]   [Full Text] [Related]  

  • 29. Agony for researchers as mix-up forces retraction of ecstasy study.
    Knight J
    Nature; 2003 Sep; 425(6954):109. PubMed ID: 12968135
    [No Abstract]   [Full Text] [Related]  

  • 30. Emerging treatments for PTSD.
    Cukor J; Spitalnick J; Difede J; Rizzo A; Rothbaum BO
    Clin Psychol Rev; 2009 Dec; 29(8):715-26. PubMed ID: 19800725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is the 3,4-Methylenedioxymethamphetamine assisted psychotherapy a novel approach to managing post-traumatic stress disorder?
    Nafees T; Wase HA; Amir Malik MF
    J Pak Med Assoc; 2019 Aug; 69(8):1229. PubMed ID: 31431790
    [No Abstract]   [Full Text] [Related]  

  • 32. [Ecstasy is a dangerous drug the society chooses to ignore].
    Heilig M
    Lakartidningen; 2003 Feb; 100(9):688-90. PubMed ID: 12674555
    [No Abstract]   [Full Text] [Related]  

  • 33. MDMA assisted therapy: Three papers are retracted as FDA rejects PTSD application.
    Mahase E
    BMJ; 2024 Aug; 386():q1798. PubMed ID: 39137950
    [No Abstract]   [Full Text] [Related]  

  • 34. Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.
    Alpert MD; O'Donnell KC; Paleos CA; Sola E; Stauffer CS; Wagner AC; Nicholas CR; Mithoefer MC
    Am J Psychiatry; 2024 Jan; 181(1):76-77. PubMed ID: 38161307
    [No Abstract]   [Full Text] [Related]  

  • 35. MDMA ("ecstasy") and neurotoxicity.
    Mithoefer M; Jerome L; Doblin R
    Science; 2003 Jun; 300(5625):1504-5; author reply 1504-5. PubMed ID: 12791964
    [No Abstract]   [Full Text] [Related]  

  • 36. Receptors acting through adenylate cyclase in the CNS.
    Wollemann M
    Acta Physiol Acad Sci Hung; 1980; 55(4):299-304. PubMed ID: 6258390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substance abuse. From ecstasy to agony.
    Jones C; Dickinson P
    Nurs Times; 1992 Mar 25-31; 88(13):27-30. PubMed ID: 1363615
    [No Abstract]   [Full Text] [Related]  

  • 38. Designer drugs--the Ecstasy and the agony.
    Kua EH
    Singapore Med J; 1997 Jan; 38(1):6. PubMed ID: 9269344
    [No Abstract]   [Full Text] [Related]  

  • 39. Repeated administration of AC-5216, a ligand for the 18 kDa translocator protein, improves behavioral deficits in a mouse model of post-traumatic stress disorder.
    Qiu ZK; Zhang LM; Zhao N; Chen HX; Zhang YZ; Liu YQ; Mi TY; Zhou WW; Li Y; Yang RF; Xu JP; Li YF
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():40-6. PubMed ID: 23624119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
    Richelson E
    J Clin Psychiatry; 1984 Aug; 45(8):331-6. PubMed ID: 6146602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.